Is CRISPR Therapeutics Stock Yesterday's News? [Yahoo! Finance]
How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors [Yahoo! Finance]
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term [Yahoo! Finance]
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $80.00 price target on the stock.
CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $86.00 price target on the stock.